Martoma To Stand Trial In November

Jun 6 2013 | 11:29am ET

Mathew Martoma, the former SAC Capital Advisors portfolio manager whose alleged insider-trading has brought that firm to its knees, will face trial later this year on fraud charges.

U.S. District Judge Paul Gardephe said yesterday that Martoma's trial will begin on Nov. 4. He is accused of earning SAC about $276 million in illicit profits trading on tips about Alzheimer's disease drug trials.

Martoma's lawyer, Richard Strassberg, told Gardephe he might need more time, citing both the prosecution's apparent plan to file a superseding indictment and another trial that he is working on.

Strassberg asked Gardephe to set a February trial date. The judge said he was reluctant to do so, but told Strassberg he would postpone the trial if necessary.

"I'm not closing the door to a later trial date, but if you feel, as you get close to your trial date before Judge Rakoff, that you're facing insurmountable difficulties or that you'll still be on trial before Judge Rakoff, you'll alert me to that and I'll make an appropriate adjournment."

Martoma is accused of illegally trading shares of Elan Corp. and Wyeth, based on tips received from a doctor overseeing the drug trials. The doctor, Sidney Gilman, is a former professor at the University of Michigan and is cooperating with the probe.

Strassberg told Gardephe that he might seek to have the charges related to Elan, which is based in Dublin and trades abroad, dismissed, citing a 2010 U.S. Supreme Court ruling that U.S. securities laws do not protect foreign investors who trade overseas.

In addition, Gardephe set a June 18 conference to discuss Michigan's reluctance to give lawyers from both sides access to Gilman's computer at the university, which says it is wary of producing confidential information about drug trials and patients.

"If the university's position is that they want to quash a subpoena, I want a filing from them," Gardephe said.

The case against Martoma is the only one of the nine brought so far against SAC employees that is directly tied to firm founder Steven Cohen. Prosecutors do not, however, allege that Cohen knew the information he got from Martoma was non-public.


In Depth

Exotic Assets: Investing In Rare Violins

Jan 17 2017 | 4:43pm ET

By definition, alternative investments include exotic assets far beyond your typical...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

The Trump Administration: What It Could Mean for Carried Interest

Jan 19 2017 | 5:25pm ET

The arrival of the Trump administration brings the potential for a repeal of the...

 

From the current issue of

Often seen as a passion project, or part of a philanthropic venture, rare and fine stringed instruments offer an exciting option to diversify one’s investment portfolio while providing an opportunity for an exceptional long-term investment.